Extranodal NK-T-cell lymphoma staging: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 16: | Line 16: | ||
! style="background: #4479BA;; color:#FFF;" | Group | ! style="background: #4479BA;; color:#FFF;" | Group | ||
! style="background: #4479BA;; color:#FFF;" | Altered factors count | ! style="background: #4479BA;; color:#FFF;" | Altered factors count | ||
!5 year prognosis | ! style="background: #4479BA;; color:#FFF;" |5 year prognosis | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | N.O. | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | N.O. | ||
|81000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 81000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 1 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | ||
|64000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 64000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 2 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | ||
|34000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 34000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 4 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 4 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 3/More | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3/More | ||
|7000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 7000 out of 100000 | ||
|} | |} | ||
==References== | ==References== |
Revision as of 14:59, 27 August 2019
Extranodal NK-T-cell lymphoma Microchapters |
Differentiating Extranodal NK-T-cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Extranodal NK-T-cell lymphoma staging On the Web |
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma staging |
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Staging
Extranodal NK/T cell lymphoma survival rate is not well predicted by Ann Arbor staging system.[1] A new system was introduced by a Korean study based on B symptoms, Ann Arbor system, LDH level, and regional lymphadenopathy combined.[2]Four risk groups identified as below:
- group 1: No adverse factor
- group 2: One factor
- group 3: Two factors
- group 4: Three or more factors
Group | Altered factors count | 5 year prognosis |
---|---|---|
1 | N.O. | 81000 out of 100000 |
2 | 1 | 64000 out of 100000 |
3 | 2 | 34000 out of 100000 |
4 | 3/More | 7000 out of 100000 |
References
- ↑ . doi:10.1111/j.1349-7006.2009.01319.x. Check
|doi=
value (help). Missing or empty|title=
(help) - ↑ Lee, Jeeyun; Suh, Cheolwon; Park, Yeon Hee; Ko, Young H.; Bang, Soo Mee; Lee, Jae Hoon; Lee, Dae Ho; Huh, Jooryung; Oh, Sung Yong; Kwon, Hyuk-Chan; Kim, Hyo Jin; Lee, Soon Il; Kim, Jung Han; Park, Jinny; Oh, Seok Joong; Kim, Kihyun; Jung, Chulwon; Park, Keunchil; Kim, Won Seog (2006). "Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study". Journal of Clinical Oncology. 24 (4): 612–618. doi:10.1200/JCO.2005.04.1384. ISSN 0732-183X.